18F-FPyCO/SMBT-1 for Parkinson's (NCT07685873)
Detect Parkinson disease related lesions
- Trial ID
- NCT07685873
- Official Title
- Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
- Goal
- Detect Parkinson disease related lesions
- Status
- RECRUITING
- Sponsor
- Tianjin Medical University
- Study Type
- OBSERVATIONAL
- Enrollment
- 200 participants
- Conditions
- Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
- Interventions
- Diagnostic Test: 18F-FPyCO/SMBT-1
Summary For Families
The goal is to see whether a new PET/CT imaging agent, called 18F-FPyCO/SMBT-1, can help detect primary and metastatic lesions in conditions linked to the enzyme monoamine oxidase B, including Parkinson disease and related disorders. Participants get a PET/CT scan with the agent; researchers will measure how much tracer shows up in lesions using the maximum standard uptake value, and then calculate how well the scan finds true disease and avoids false alarms. The study is looking for adults 18 to 90 years old with suspected, newly diagnosed, or previously treated Parkinson disease or related conditions who are already scheduled for a PET/CT scan and can give informed consent; pregnant people and those with non-malignant lesions are excluded.
Locations
- The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
- Tianjin Medical University General Hospital, Tianjin, Tian, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Diagnostic Test: 18F-FPyCO/SMBT-1. The goal is to see whether a new PET/CT imaging agent, called 18F-FPyCO/SMBT-1, can help detect primary and metastatic lesions in conditions linked to the enzyme monoamine oxidase B, including Parkinson disease and related disorders. Participants get a PET/CT scan with the agent; researchers will measure how much tracer shows up in lesions using the maximum standard uptake value, and then calculate how well the scan finds true disease and avoids false alarms. The study is looking for adults 18 to 90 years old with suspected, newly diagnosed, or previously treated Parkinson disease or related conditions who are already scheduled for a PET/CT scan and can give informed consent; pregnant people and those with non-malignant lesions are excluded.
- Who can participate?
- Participants must be between 18 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- How many visits does this trial involve?
- Each subject will have a single study injection and imaging visit; timing is described only as "within the specificed time".
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Intravenous infusion (minimally invasive); Injection (minimally invasive); PET scan (minimally invasive); MRI scan (non-invasive). Confirm the full schedule with the study coordinator.